DermaSensor Product Brochure
Better decisions, better detection, more accurate management DermaSensor empowers physicians by providing objective, actionable risk results to aid in skin cancer detection by assessing cellular and sub-cellular features that cannot be seen visually or dermoscopically.
Features
- Handheld, portable design
- Non-invasive optical spectroscopy
- Beneath the skin, cellular-level analysis
- Immediate objective results
- AI-powered, ultra-miniaturized ESS technology
Indications for use
The DermaSensor™ device is indicated for evaluating skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients aged 40 and above, to assist in the decision to refer the patient to a dermatologist.
The DermaSensor device should be used in conjunction with the totality of clinically relevant information from the clinical assessment, including visual analysis of the lesion, by physicians who are not dermatologists. The device should be used on lesions already assessed as suspicious for skin cancer and not as a screening tool.
The device should not be used as the sole diagnostic criterion nor to confirm clinical diagnosis of skin cancer.
An automated, AI-powered lesion assessment in seconds
AI-powered spectroscopy technology
Xenon lamp pulses light to take ~1mm3 optical tissue samples of cellular features.
The device analyses spectral data across 47 wavelengths for malignancy risk.
The 0-10 output corresponded to a cancer likelihood of 3% (0) to 61% (10)1.
References:
- Merry SP, Croghan IT, Dukes KA, et al. Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer.
Journal of Primary Care & Community Health. 2025;16. doi:10.1177/21501319251344423 - Seiverling EV, et al. Clinical Utility of an Elastic Scattering Spectroscopy Device in Assisting Primary Care Physicians’ Detection of Skin Cancers.
Poster Presentation, Maui Derm Hawaii Conference, Wailea, HI, January 24-28, 2023. - Ferris LK, Jaklitsch E, Seiverling EV, et al. DERM-SUCCESS FDA Pivotal Study: A Multi-Reader Multi-Case Evaluation of Primary Care Physicians’ Skin Cancer Detection
Using AI-Enabled Elastic Scattering Spectroscopy. J Prim Care Community Health. 2025;16:21501319251342106. doi:10.1177/21501319251342106 - Hartman RI et al., JAAD International (2023), doi: 10.1016/j.jdin.2023.10.0.
- Seiverling, E.V. (2025). JCAD MRMC Study. Journal of Clinical and Aesthetic Dermatology, October 2025, 58–65. Link
- Jaklitsch, E., Chang, S., Bruno, S., D’Angelo, N., Tung, J.K., Ferris, L.K. (2025). Prospective evaluation of an AI-enabled ESS device for triage of patient-identified skin lesions
in dermatology clinics. JAAD International, Dec 2025. Mendeley Supplementary Data
The only FDA Breakthrough skin cancer detection device designed for PCPs
Disclaimer – The coding and reimbursement information provided in this document is derived from the American Medical Association’s Current Procedural Technology (CPT) as well as the
Centers for Medicare and Medicaid Services’ (CMS) website and copyrighted code sets, 2026. All ICD-10-CM, ICD-10-PCS, CPT, and HCPCS codes referenced herein are for informational
purposes only. It is the responsibility of the rendering provider to determine and report appropriate codes, modifiers, and charges for health care services rendered to patients in their care.
DermaSensor cannot promise or guarantee that a provider’s selection of the codes identified herein are appropriate for a particular procedure or will result in reimbursement from any thirdparty payer. Questions related to specific coding and coverage policies should be directed to the applicable third-party payer.
The Current Procedural Terminology (CPT) code set is a medical code set copyrighted and maintained by the American Medical Association (AMA) through the CPT Editorial Panel.
The information in this table is an abstract of over 200 Unlisted procedural CPT codes and is provided as a reference in this Guide. Refer to the list of over 200 Unlisted procedural CPT
codes for alternative codes that may be deemed more appropriate.
Refer to the Coding Guide for additional information on coding and reimbursement for the DermaSensor procedure.
*The APC Payment amount in Table 1 is for the Outpatient Prospective Payment System (OPPS). Providers billing under site of service 11 are not paid under the OPPS.
Payment will be determined by the Medicare contractor or pursuant to payer contract.
**(RW): Relative Weight
These amounts reflect historical paid claims and do not guarantee or predict coverage or reimbursement for future claims.
*The average, minimum, and maximum payment amounts shown above reflect paid claims and are based on historical claims data collected from DermaSensor users between January 1,
2026 and July 20, 2026. These historical payment amounts are provided for informational purposes only and do not represent a fee schedule or guarantee that any claim will be covered or
paid. Coverage and payment vary by payer, plan, provider contract, coding, documentation and the circumstances of the particular claim.
DermaSensor Inc. is a medical device company that enables healthcare professionals to effectively check for skin cancer by leveraging cuttingedge technologies. The DermaSensor™ device is a cost effective handheld tool that uses artificial intelligence and spectroscopy to non-invasively test skin lesions for skin cancer risk in seconds. By enabling quick and effective skin cancer checks, DermaSensor ultimately hopes to improve skin cancer detection and save lives. DermaSensor is currently FDA Cleared, and is available for sale in the U.S.
